- Home
- GALT vs KINS Comparison
GALT vs KINS Comparison
Compare GALT & KINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GALT | KINS |
|---|---|---|
| Founded | 2000 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.0M | 291.4M |
| IPO Year | 2008 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GALT | KINS |
|---|---|---|
| Price | $3.54 | $19.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 149.1K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.18% |
| EPS Growth | 36.84 | ★ 94.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $214,867,301.00 |
| Revenue This Year | N/A | $24.23 |
| Revenue Next Year | N/A | $18.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 38.50 |
| 52 Week Low | $2.03 | $13.08 |
| 52 Week High | $7.13 | $20.79 |
Technical Indicators
Market Signals| Indicator | GALT | KINS |
|---|---|---|
| Relative Strength Index (RSI) | 45.02 | 58.28 |
| Support Level | $2.30 | $14.37 |
| Resistance Level | $4.35 | $20.79 |
| Average True Range (ATR) | 0.49 | 0.70 |
| MACD | -0.18 | -0.22 |
| Stochastic Oscillator | 9.01 | 51.03 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About KINS Kingstone Companies Inc.
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.